Daratumumab, a monoclonal antibody, may merit consideration as a treatment for patients with severe refractory pulmonary and cutaneous ANCA-associated vasculitis (AAV), according to the authors of ...

In ANCA-associated vasculitis, there is severe inflammation of the smaller and medium-sized blood vessels in the lungs. In addition, the skin and kidneys may also be affected.

Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group; Avacopan for the Treatment of ANCA-Associated Vasculitis; N Engl J Med. 2021 Feb 18;384 (7):599-609. doi: 10.1056/NEJMoa2023386.

Emerging ANCA Vasculitis therapies in the different phases of clinical trials are- MT-2990, KYV-101, Povetacicept, NM8074, Sparsentan, Abatacept, BDB-001 injection, Avacopan, Iptacopan, ALE.F02 ...

The Kidney Disease: Improving Global Outcomes organization has published a new guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The 46-page ...

Vasculitis can result from an autoimmune condition, infections, or medications and causes a rash. Learn more about how it affects the skin.

In 2022, the market size of ANCA Associated Vasculitis was highest in the US among the 7MM, accounting for approximately USD 620 million, which is expected to increase by 2032.

Patients with ANCA-associated vasculitis are at risk for life-threatening complications, organ damage, toxic effects from medications used to treat the disorder, and deterioration of health ...

“ANCA-associated vasculitis is officially designated an intractable disease in Japan, indicating a rare disease without any effective treatment but for which long-term treatment is required. There is ...